Pluripotent therapeutic compositions and uses thereof

Abstract

Synthetic Stem Cell-like Tissue Healing and Regeneration Medication with Anti-inflammatory, Protein Synthesis, Enzyme Deficiency Activation and Genetic Therapy, and Anti-cancer Agent derived from a series of inventions that include these products of Biomolecular Engineering, Drug Discovery from a Biologic Periodic Table of Applied Biochemistry and Biophysics. Tissue has a self healing effect promoting tissue healing and tissue regeneration. Not only does it maintain good health but also it has been observed that the patient's blood is withdrawn from the patient and applied to the ulcer has healing qualities. Cartilage placed in a wound promotes and accelerates wound healing. The anabolic biochemical and biophysical equivalent of tissue has been found in these embodiments to have the same pharmacologic qualities, when devoid of genetic DNA mismatch and other catabolic factors including the catabolic effects of microorganism overgrowth that lacks pro-biotic qualities. The healing efficacy of these tissue components gives us further appreciation of the protective action of human tissue over and above and other than the immune protective system or perhaps an integral component part of the immune system.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS[0001]This application is a continuation-in-part of U.S. application Ser. No. 10 / 868,697, filed Jun. 14, 2004, which claims the benefit of U.S. Provisional Patent Application Ser. Nos. 60 / 577,120, filed tune 4, 2004; 60 / 557,584; filed Mar. 29, 2004; 60 / 550,797, filed Mar. 5, 2004; 60 / 478,565, filed Jun. 12, 2003; 60 / 493,237, filed Aug. 6, 2003; and 60 / 523,936, filed Nov. 21, 2003. These applications are all hereby incorporated by reference in their entireties, including all figures, formulae, references, amino acid and nucleic acid sequences, and tables.[0002]This application is a continuation-in-part of U.S. application Ser. No. 10 / 868,697, filed Jun. 14, 2004, which is a continuation-in-part of application Ser. No. 10 / 765,664, filed Jan. 26, 2004 which claims the benefit of U.S. Provisional Patent Application Ser. Nos. 60 / 442,278, filed Jan. 24, 2003; 60 / 447,779, filed Feb. 13, 2003; 60 / 448,003, filed Feb. 18, 2003; 60 / 448,497, filed Feb. 19,...

AI Technical Summary

Benefits of technology

[0100]Component No. 3: The extracellular matrix can be given in the form of 740 mg capsules, 4 to 6 capsules 3 times daily. The capsules comprise a proteoglycan aggregate complex of cartilage, chondroitin sulfate covalently bonded to core proteins, further non-covalently linked to macro molecule of hyaluronic acid and collagen (see for example, Cartilade, BioTherapies, Inc., Fairfield, N.J.). Component No. 3 is therapeutically used along with component No. 2 self-vesiculating phosphatidylcholine with HLB of 10 to 11 and will further protect the cell and tissue.

[0273]The gel hydrate of the colloidal domain is remarkable and unique to this new drug discovery technology and Q101KC. Component Nos. 1, 2 and part of Component No. 3 with its lipid cell membrane anchor glypicans are similarly effectual in tissue regeneration and healing. The liquid crystal of all these forgoing components of emulsion technology aid in their liquid crystal alignment effects in the healing of diseased tissue as in CD.Description of the Rare Disease or Condition, Proposed Indication, and Reason for Therapy.

Problems solved by technology

It describes the clinical effects that are commonly observed, and indicates what treatments may be helpful.Unfortunately, in too many instances, including nuclear radiation, no active treatment is offerable that can save the patient.

Images